A Window That Closes: Why Timing Matters in IgG4-Related Disease

Allison Yang, M.D., M.P.H., medical director of the Pancreas Program at Weill Cornell Medicine, said one of the strongest signals for IgG4-related disease is a mismatch between imaging and pathology: scans that look concerning for cancer paired with a negative biopsy. Involvement of multiple organs, such as pancreas findings alongside swollen salivary or lacrimal glands or bile duct strictures, is another major indicator, as is a diffusely enlarged, “sausage-shaped” pancreas rather than a focal mass. More broadly, Yang said the disease tends to present as a picture that doesn’t cleanly fit either classic acute pancreatitis or classic pancreatic cancer. She noted that a normal IgG4 blood level does not rule out the disease and shouldn’t be used to dismiss it as a possibility.

A Long and Costly Diagnostic Journey

Because IgG4-related disease frequently mimics pancreatic cancer on imaging, Yang said patients often undergo extensive cancer workups, including multiple biopsies, ERCPs, biliary stents and sometimes surgery, before the correct diagnosis is identified. That process can mean losing part of a healthy organ to a procedure that steroids might have addressed instead. Yang said patients are typically relieved to learn they don’t have cancer but often frustrated by how long the diagnostic process took, describing an emotional toll that comes with repeated testing and multiple subspecialty visits over an extended period.

Why Timing Affects Long-Term Outcomes

Yang described the disease as involving a narrowing window for effective treatment. While active inflammation generally responds well to steroids, untreated inflammation can progress to fibrosis, or scarring, which is permanent. Once patients develop signs of pancreatic insufficiency, such as diabetes or malabsorption, that tissue damage is typically not reversible. Every month a diagnosis is delayed, Yang said, more tissue shifts from a treatable inflammatory state into permanent scarring, and medicine currently has no way to reverse fibrosis once it sets in. That, she said, is why keeping IgG4-related disease on the differential early, even in atypical cases, matters both for reaching an accurate diagnosis and for preserving as much organ function as possible before the disease progresses past the point of intervention.